Q-omics provides the consensus-scored DEFB136 profile across patient tissues and cancer cell-line models. DEFB136 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DEFB136 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, DEFB136 RNA expression shows 6,346 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRC, and STAD as cancer lineages where DEFB136 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB136 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB136 survival associations across molecular data types. DEFB136 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB136 RNA expression–survival associations across cancer types. High DEFB136 expression shows unfavorable associations in BLCA, LUSC, UCS, KIRC, KIRP and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DEFB136 RNA expression.
This table summarizes DEFB136 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB136. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB136 shows higher tumor expression in KIRC, ESCA, THCA, LUAD and COAD. The KIRC box plot shows higher DEFB136 RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p = .004).
This table shows molecular features associated with DEFB136 in patient tissues and cancer cell lines. In patient samples, DEFB136 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB136 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
